Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Christos Thomadakis; Ilias Gountas; Erika Duffell; Konstantinos Gountas; Benjamin Bluemel; Thomas Seyler; Filippo Maria Pericoli; Irene Kászoni-Rückerl; Ziad el-Khatib; Martin Busch; Irene Schmutterer; Thomas Vanwolleghem; Sofieke Klamer; Els Plettinckx; Laure Mortgat; Dominique van Beckhoven; Tonka Varleva; Mirjana Lana Kosanovic Licina; Tatjana Nemeth Blazic; Diana Nonković; Fanitsa Theophanous; Vratislav Nemecek; Marek Maly; Peer Brehm Christensen; Susan Cowan; Kristi Rüütel; Henrikki Brummer-Korvenkontio; C. cile Brouard; Gyde Steffen; Amrei Krings; Sandra Dudareva; Ruth Zimmermann; Georgia Nikolopoulou; Zsuzsanna Molnár; Emese Kozma; Magnús Gottfredsson; Niamh Murphy; Loreta A. Kondili; Maria Elena Tosti; Anna Rita Ciccaglione; Barbara Suligoi; Raina Nikiforova; Renate Putnina; Ligita Jancoriene; Carole Seguin-Devaux; Tanya Melillo; Anders Boyd; Marc van der Valk; Eline op de Coul; Robert Whittaker; Hilde Kløvstad; Małgorzata Stępień; Magdalena Rosińska; Cristina Valente; Rui Tato Marinho; Odette Popovici; M. ria Avdičová; Jana Kerlik; Irena Klavs; Mojca Maticic; Asuncion Diaz; Julia del Amo; Josefine Lundberg Ederth; Maria Axelsson; Georgios Nikolopoulos

doi:10.1016/j.lanepe.2023.100792

Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Christos Thomadakis
, Ilias Gountas^*
, Erika Duffell
, Konstantinos Gountas
, Benjamin Bluemel
, Thomas Seyler
, Filippo Maria Pericoli
, Irene Kászoni-Rückerl
, Ziad el-Khatib
, Martin Busch
, Irene Schmutterer
, Thomas Vanwolleghem
, Sofieke Klamer
, Els Plettinckx
, Laure Mortgat
, Dominique van Beckhoven
, Tonka Varleva
, Mirjana Lana Kosanovic Licina
, Tatjana Nemeth Blazic
, Diana Nonković

Fanitsa Theophanous, Vratislav Nemecek, Marek Maly, Peer Brehm Christensen, Susan Cowan, Kristi Rüütel, Henrikki Brummer-Korvenkontio, C. cile Brouard, Gyde Steffen, Amrei Krings, Sandra Dudareva, Ruth Zimmermann, Georgia Nikolopoulou, Zsuzsanna Molnár, Emese Kozma, Magnús Gottfredsson, Niamh Murphy, Loreta A. Kondili, Maria Elena Tosti, Anna Rita Ciccaglione, Barbara Suligoi, Raina Nikiforova, Renate Putnina, Ligita Jancoriene, Carole Seguin-Devaux, Tanya Melillo, Anders Boyd, Marc van der Valk, Eline op de Coul, Robert Whittaker, Hilde Kløvstad, Małgorzata Stępień, Magdalena Rosińska, Cristina Valente, Rui Tato Marinho, Odette Popovici, M. ria Avdičová, Jana Kerlik, Irena Klavs, Mojca Maticic, Asuncion Diaz, Julia del Amo, Josefine Lundberg Ederth, Maria Axelsson, Georgios Nikolopoulos^*

^*Corresponding author for this work

University of Cyprus Medical School, Nicosia, Cyprus
European Centre for Disease Prevention and Control
European Monitoring Centre for Drugs and Drug Addiction
Health
Austrian Agency for Health and Food Safety GmbH
Gesundheit Österreich GmbH
University of Antwerp
Sciensano
Medical University of Pleven
University of Zagreb
Croatian National Institute of Public Health
Teaching Public Health Institute of Split-Dalmatia County
University of Split
Ministry of Health, Cyprus
Czech National Institute of Public Health
University of Southern Denmark
Statens Serum Institut
National Institute of Health Development
National Institute for Health and Welfare
French Public Health Agency, St Maurice, France
Robert Koch-Institut
National Public Health Organization
National Center for Public Health
University of Iceland
Landspitali University Hospital
Health Protection Surveillance Centre
Istituto Superiore di Sanita
Saint Camillus International University of Health and Medical Sciences, Rome, Italy
Centre for Disease Prevention and Control, Riga, Latvia
Vilnius University
Luxembourg Institute of Health
Ministry for Health
Municipal Health Service of Amsterdam
HIV Monitoring Foundation, Amsterdam, Netherlands
Amsterdam UMC
National Institute of Public Health and the Environment
Norwegian Institute of Public Health
National Medicines Institute, Warsaw
University of Coimbra
University of Lisbon
Institutul de Sanatate Publica
Banska Bystrica Regional Authority of Public Health, Banska Bystrica, Slovakia
National Institute of Public Health of Slovenia
University of Ljubljana
Centro de Investigación Biomédica en Red
STI
Public Health Agency of Sweden
Federal Ministry of Social Affairs, Health, Care and Consumer Protection, Vienna, Austria
Institute for Surveillance & Infectious Disease Epidemiology
Austrian National Public Health Institute
Antwerp University Hospital and University of Antwerp
Department of Epidemiology and public health, Brussels, Belgium
Medical University (Army Medical University), Chongqing, 400038, China
Andrija Stampar Teaching Institute of Public Health
Teaching Institute of Public Health Split and Dalmatia County
Health Polytechnic of Health Ministry Tasikmalaya
National Public Health Institute
Department of Oncology, Odense University Hospital, Odense, Denmark
Department of Infectious Disease Epidemiology and Prevention
National Institute for Health Development
Finnish Institute for Health and Welfare
Santé publique France
Robert Koch Institute
National Center for Public Health and Pharmacy
The National University Hospital in Iceland, Iceland
HSE Health Protection Surveillance Centre
National Center for Global Health and Medicine
Viral Hepatitis
National AIDS Unit
The Centre for Disease Prevention and Control
Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Infectious Disease Prevention and Control Unit
National Institute for Public Health and the Environment (RIVM)
National Institute of Public Health NIH - National Research Institute
Department of Infectious Diseases
Medical School of Lisbon
National Institute of Public Health, Bucharest, Romania
Department of Clinical Epidemiology
Institute of Health Carlos III
US Centers for Disease Control and Prevention, Nairobi, Kenya: Division of Global HIV/AIDS

Research output: Contribution to journal › Article › Academic › peer-review

38 Downloads (Pure)

Abstract

Background: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. Funding: ECDC.

Original language	English
Article number	100792
Pages (from-to)	100792
Journal	The Lancet Regional Health - Europe
Volume	36
DOIs	https://doi.org/10.1016/j.lanepe.2023.100792
Publication status	Published - 1 Jan 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Chronic hepatitis
Elimination
Europe
HCV
Hepatitis C
Prevalence

Access to Document

10.1016/j.lanepe.2023.100792

Prevalence-of-chronic-hcv-infection-in-eueea-countries-in-2019-using-multiparameter-evidence-synthesis.pdfFinal published version, 992 KBLicence: CC BY

Cite this

Thomadakis, C., Gountas, I., Duffell, E., Gountas, K., Bluemel, B., Seyler, T., Pericoli, F. M., Kászoni-Rückerl, I., el-Khatib, Z., Busch, M., Schmutterer, I., Vanwolleghem, T., Klamer, S., Plettinckx, E., Mortgat, L., van Beckhoven, D., Varleva, T., Kosanovic Licina, M. L., Nemeth Blazic, T., ... Nikolopoulos, G. (2024). Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis. The Lancet Regional Health - Europe, 36, 100792. Article 100792. https://doi.org/10.1016/j.lanepe.2023.100792

@article{f6ec49b699b54619819d47a009abce01,

title = "Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis",

abstract = "Background: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50\% [95\% Credible Interval (CrI): 0.46\%, 0.55\%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88\%; 95\% CrI: 0.81\%, 0.94\%). At least 35.76\% (95\% CrI: 33.07\%, 38.60\%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. Funding: ECDC.",

keywords = "Chronic hepatitis, Elimination, Europe, HCV, Hepatitis C, Prevalence",

author = "Christos Thomadakis and Ilias Gountas and Erika Duffell and Konstantinos Gountas and Benjamin Bluemel and Thomas Seyler and Pericoli, \{Filippo Maria\} and Irene K{\'a}szoni-R{\"u}ckerl and Ziad el-Khatib and Martin Busch and Irene Schmutterer and Thomas Vanwolleghem and Sofieke Klamer and Els Plettinckx and Laure Mortgat and \{van Beckhoven\}, Dominique and Tonka Varleva and \{Kosanovic Licina\}, \{Mirjana Lana\} and \{Nemeth Blazic\}, Tatjana and Diana Nonkovi{\'c} and Fanitsa Theophanous and Vratislav Nemecek and Marek Maly and Christensen, \{Peer Brehm\} and Susan Cowan and Kristi R{\"u}{\"u}tel and Henrikki Brummer-Korvenkontio and Brouard, \{C. cile\} and Gyde Steffen and Amrei Krings and Sandra Dudareva and Ruth Zimmermann and Georgia Nikolopoulou and Zsuzsanna Moln{\'a}r and Emese Kozma and Magn{\'u}s Gottfredsson and Niamh Murphy and Kondili, \{Loreta A.\} and Tosti, \{Maria Elena\} and Ciccaglione, \{Anna Rita\} and Barbara Suligoi and Raina Nikiforova and Renate Putnina and Ligita Jancoriene and Carole Seguin-Devaux and Tanya Melillo and Anders Boyd and \{van der Valk\}, Marc and \{op de Coul\}, Eline and Robert Whittaker and Hilde Kl{\o}vstad and Ma{\l}gorzata St{\c e}pie{\'n} and Magdalena Rosi{\'n}ska and Cristina Valente and Marinho, \{Rui Tato\} and Odette Popovici and Avdi{\v c}ov{\'a}, \{M. ria\} and Jana Kerlik and Irena Klavs and Mojca Maticic and Asuncion Diaz and \{del Amo\}, Julia and \{Lundberg Ederth\}, Josefine and Maria Axelsson and Georgios Nikolopoulos",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2024",

month = jan,

day = "1",

doi = "10.1016/j.lanepe.2023.100792",

language = "English",

volume = "36",

pages = "100792",

journal = "The Lancet Regional Health - Europe",

issn = "2666-7762",

publisher = "Elsevier Ltd",

}

Thomadakis, C, Gountas, I, Duffell, E, Gountas, K, Bluemel, B, Seyler, T, Pericoli, FM, Kászoni-Rückerl, I, el-Khatib, Z, Busch, M, Schmutterer, I, Vanwolleghem, T, Klamer, S, Plettinckx, E, Mortgat, L, van Beckhoven, D, Varleva, T, Kosanovic Licina, ML, Nemeth Blazic, T, Nonković, D, Theophanous, F, Nemecek, V, Maly, M, Christensen, PB, Cowan, S, Rüütel, K, Brummer-Korvenkontio, H, Brouard, CC, Steffen, G, Krings, A, Dudareva, S, Zimmermann, R, Nikolopoulou, G, Molnár, Z, Kozma, E, Gottfredsson, M, Murphy, N, Kondili, LA, Tosti, ME, Ciccaglione, AR, Suligoi, B, Nikiforova, R, Putnina, R, Jancoriene, L, Seguin-Devaux, C, Melillo, T, Boyd, A , van der Valk, M, op de Coul, E, Whittaker, R, Kløvstad, H, Stępień, M, Rosińska, M, Valente, C, Marinho, RT, Popovici, O, Avdičová, MR, Kerlik, J, Klavs, I, Maticic, M, Diaz, A, del Amo, J, Lundberg Ederth, J, Axelsson, M & Nikolopoulos, G 2024, 'Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis', The Lancet Regional Health - Europe, vol. 36, 100792, pp. 100792. https://doi.org/10.1016/j.lanepe.2023.100792

TY - JOUR

T1 - Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

AU - Thomadakis, Christos

AU - Gountas, Ilias

AU - Duffell, Erika

AU - Gountas, Konstantinos

AU - Bluemel, Benjamin

AU - Seyler, Thomas

AU - Pericoli, Filippo Maria

AU - Kászoni-Rückerl, Irene

AU - el-Khatib, Ziad

AU - Busch, Martin

AU - Schmutterer, Irene

AU - Vanwolleghem, Thomas

AU - Klamer, Sofieke

AU - Plettinckx, Els

AU - Mortgat, Laure

AU - van Beckhoven, Dominique

AU - Varleva, Tonka

AU - Kosanovic Licina, Mirjana Lana

AU - Nemeth Blazic, Tatjana

AU - Nonković, Diana

AU - Theophanous, Fanitsa

AU - Nemecek, Vratislav

AU - Maly, Marek

AU - Christensen, Peer Brehm

AU - Cowan, Susan

AU - Rüütel, Kristi

AU - Brummer-Korvenkontio, Henrikki

AU - Brouard, C. cile

AU - Steffen, Gyde

AU - Krings, Amrei

AU - Dudareva, Sandra

AU - Zimmermann, Ruth

AU - Nikolopoulou, Georgia

AU - Molnár, Zsuzsanna

AU - Kozma, Emese

AU - Gottfredsson, Magnús

AU - Murphy, Niamh

AU - Kondili, Loreta A.

AU - Tosti, Maria Elena

AU - Ciccaglione, Anna Rita

AU - Suligoi, Barbara

AU - Nikiforova, Raina

AU - Putnina, Renate

AU - Jancoriene, Ligita

AU - Seguin-Devaux, Carole

AU - Melillo, Tanya

AU - Boyd, Anders

AU - van der Valk, Marc

AU - op de Coul, Eline

AU - Whittaker, Robert

AU - Kløvstad, Hilde

AU - Stępień, Małgorzata

AU - Rosińska, Magdalena

AU - Valente, Cristina

AU - Marinho, Rui Tato

AU - Popovici, Odette

AU - Avdičová, M. ria

AU - Kerlik, Jana

AU - Klavs, Irena

AU - Maticic, Mojca

AU - Diaz, Asuncion

AU - del Amo, Julia

AU - Lundberg Ederth, Josefine

AU - Axelsson, Maria

AU - Nikolopoulos, Georgios

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Background: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. Funding: ECDC.

AB - Background: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. Funding: ECDC.

KW - Chronic hepatitis

KW - Elimination

KW - Europe

KW - HCV

KW - Hepatitis C

KW - Prevalence

UR - https://www.scopus.com/pages/publications/85180548657

U2 - 10.1016/j.lanepe.2023.100792

DO - 10.1016/j.lanepe.2023.100792

M3 - Article

C2 - 38188273

SN - 2666-7762

VL - 36

SP - 100792

JO - The Lancet Regional Health - Europe

JF - The Lancet Regional Health - Europe

M1 - 100792

ER -

Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this